All In Biotech

NDA 216472 · Thea Pharma

Iyuzeh

Latanoprost · Ophthalmic · Prostaglandin Analog

Last checked: Nov 19, 2026Latest source record: Sep 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Dec 13, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

253

56 Phase 3, 9 recruiting

FAERS reports

638

80 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 30, 2024.

IYUZEH ™ (latanoprost ophthalmic solution) 0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. IYUZEH is a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ( 1 )

Mechanism: Latanoprost is a prostaglandin F 2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 13, 2022 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • IYUZEH · LATANOPROST 0.005% · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Latanoprost" as an intervention, any sponsor and status, largest first.

All 253 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye irritation153
  • eye pain87
  • vision blurred61
  • ocular hyperaemia57
  • intraocular pressure increased55
  • drug ineffective39
  • product quality issue39
  • dry eye33
  • eye pruritus32
  • foreign body sensation in eyes31
  • lacrimation increased27
  • headache24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201216
201329
201427
201551
201661
2017134
201848
201971
202070
202131
20231
202423
202546
202630

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Iyuzeh (Latanoprost/PF)

2024 spending

$6.7M

Beneficiaries

5,390

15,866 claims

Per beneficiary

$1,234

$9.63 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$251,562
2024$6,650,206

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 635 on PubMed

Sponsor: Thea Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.